Literature DB >> 18414213

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007.

C Sue Richards1, Sherri Bale, Daniel B Bellissimo, Soma Das, Wayne W Grody, Madhuri R Hegde, Elaine Lyon, Brian E Ward.   

Abstract

ACMG previously developed recommendations for standards for interpretation of sequence variations. We now present the updated revised recommendations. Here, we describe six interpretative categories of sequence variations: (1) sequence variation is previously reported and is a recognized cause of the disorder; (2) sequence variation is previously unreported and is of the type which is expected to cause the disorder; (3) sequence variation is previously unreported and is of the type which may or may not be causative of the disorder; (4) sequence variation is previously unreported and is probably not causative of disease; (5) sequence variation is previously reported and is a recognized neutral variant; and (6) sequence variation is previously not known or expected to be causative of disease, but is found to be associated with a clinical presentation. We emphasize the importance of appropriate reporting of sequence variations using standardized terminology and established databases, and of clearly reporting the limitations of sequence-based testing. We discuss follow-up studies that may be used to ascertain the clinical significance of sequence variations, including the use of additional tools (such as predictive software programs) that may be useful in variant classification. As more information becomes available allowing the interpretation of a new sequence variant, it is recommended that the laboratory amend previous reports and provide updated results to the physician. The ACMG strongly recommends that the clinical and technical validation of sequence variation detection be performed in a CLIA-approved laboratory and interpreted by a board-certified clinical molecular geneticist or equivalent.

Entities:  

Mesh:

Year:  2008        PMID: 18414213     DOI: 10.1097/GIM.0b013e31816b5cae

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  327 in total

Review 1.  Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities.

Authors:  Xi Lin; Wenxue Tang; Shoeb Ahmad; Jingqiao Lu; Candice C Colby; Jason Zhu; Qing Yu
Journal:  Hear Res       Date:  2012-01-14       Impact factor: 3.208

Review 2.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 3.  A new era in clinical genetic testing for hypertrophic cardiomyopathy.

Authors:  Matthew Wheeler; Aleksandra Pavlovic; Emil DeGoma; Heidi Salisbury; Colleen Brown; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-30       Impact factor: 4.132

4.  Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.

Authors:  David K Crockett; Perry G Ridge; Andrew R Wilson; Elaine Lyon; Marc S Williams; Scott P Narus; Julio C Facelli; Joyce A Mitchell
Journal:  Genome Med       Date:  2012-05-28       Impact factor: 11.117

5.  Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States.

Authors:  Marcus J Miller; Lindsay C Burrage; James B Gibson; Meghan E Strenk; Edward J Lose; David P Bick; Sarah H Elsea; V Reid Sutton; Qin Sun; Brett H Graham; William J Craigen; Victor Wei Zhang; Lee-Jun C Wong
Journal:  Mol Genet Metab       Date:  2015-09-02       Impact factor: 4.797

6.  Mutations in TBX18 Cause Dominant Urinary Tract Malformations via Transcriptional Dysregulation of Ureter Development.

Authors:  Asaf Vivante; Marc-Jens Kleppa; Julian Schulz; Stefan Kohl; Amita Sharma; Jing Chen; Shirlee Shril; Daw-Yang Hwang; Anna-Carina Weiss; Michael M Kaminski; Rachel Shukrun; Markus J Kemper; Anja Lehnhardt; Rolf Beetz; Simone Sanna-Cherchi; Miguel Verbitsky; Ali G Gharavi; Helen M Stuart; Sally A Feather; Judith A Goodship; Timothy H J Goodship; Adrian S Woolf; Sjirk J Westra; Daniel P Doody; Stuart B Bauer; Richard S Lee; Rosalyn M Adam; Weining Lu; Heiko M Reutter; Elijah O Kehinde; Erika J Mancini; Richard P Lifton; Velibor Tasic; Soeren S Lienkamp; Harald Jüppner; Andreas Kispert; Friedhelm Hildebrandt
Journal:  Am J Hum Genet       Date:  2015-07-30       Impact factor: 11.025

7.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

8.  Targeted next-generation sequencing to diagnose disorders of HDL cholesterol.

Authors:  Singh N Sadananda; Jia Nee Foo; Meng Tiak Toh; Lubomira Cermakova; Laia Trigueros-Motos; Teddy Chan; Herty Liany; Jennifer A Collins; Sima Gerami; Roshni R Singaraja; Michael R Hayden; Gordon A Francis; Jiri Frohlich; Chiea Chuen Khor; Liam R Brunham
Journal:  J Lipid Res       Date:  2015-08-08       Impact factor: 5.922

Review 9.  Whole-Exome Sequencing in the Clinic: Lessons from Six Consecutive Cases from the Clinician's Perspective.

Authors:  Amber Volk; Erin Conboy; Beverly Wical; Marc Patterson; Salman Kirmani
Journal:  Mol Syndromol       Date:  2015-02-03

10.  Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units.

Authors:  Carol Jean Saunders; Neil Andrew Miller; Sarah Elizabeth Soden; Darrell Lee Dinwiddie; Aaron Noll; Noor Abu Alnadi; Nevene Andraws; Melanie LeAnn Patterson; Lisa Ann Krivohlavek; Joel Fellis; Sean Humphray; Peter Saffrey; Zoya Kingsbury; Jacqueline Claire Weir; Jason Betley; Russell James Grocock; Elliott Harrison Margulies; Emily Gwendolyn Farrow; Michael Artman; Nicole Pauline Safina; Joshua Erin Petrikin; Kevin Peter Hall; Stephen Francis Kingsmore
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.